Farmas USA

Gnca

https://ir.genocea.com/news-releases/news-release-details/genocea-host-investor-call-highlighting-new-gen-009-clinical-and

abriremos con gaps

futuros entre +1,3 y +2

PFE

Buenos resultados de la vacuna de Pfizer

Pfizer

Vacuna. 90% efectividad

Edito: Early análisis +sparse details. Tampoco nos flipemos...
 
https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html#click=https://t.co/HThqNKKPps
Oficial:

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

PFE

Lo que decía. Primer análisis intermedio de fase III. 

Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms.

Y si.. Quizá.. Todo fuera bien..
50 million vaccine doses in 2020 and manufacture up to 1.3 billion doses in 2021.
Dos dosis.. A 28 días vista la inmunidad
Y no leo la edad target, por qué si no es segura en mayores (que son los que esta segando este jodido..) 

Va pa largo aún.. Y en ESP no se si será suficiente

@Zokatira96, @trantor y @triskis iban haciendo el seguimiento en otro hilo. Recuerdo que efectivamente varias no cumplían el requisito de abuelos. Si nadie se acuerda, hay que ir a mirarlo.

Es verdad, me sonaba... Rumor y noticia
A ver la apertura